Shelley Byrd
Family · Montgomery, ALNPI 1841576915
Payments from drug & device makers
Across 265 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$555
- Lilly USA, LLC$517
- Amgen$480
- AbbVie$410
- Pfizer$407
- AstraZeneca$390
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,62996%
- Education$1764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $555 |
| Lilly USA, LLC | 38 | $517 |
| Amgen(2 entities) | 25 | $480 |
| AbbVie | 26 | $410 |
| Pfizer | 20 | $407 |
| AstraZeneca | 20 | $390 |
| Amarin Pharma, Inc. | 11 | $221 |
| Exact Sciences | 12 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $201 |
| Astellas Pharma US Inc | 3 | $196 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $156 |
| GSK | 8 | $146 |
| Boehringer Ingelheim | 8 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $96 |
| Merck | 5 | $78 |
| Abbott | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| Johnson & Johnson | 3 | $48 |
| Dexcom, Inc. | 3 | $47 |
| Boston Scientific | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Sobi, Inc | 1 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Vertex | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Bayer | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Scynexis, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Medtronic | 1 | $16 |
| Novartis | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Vistapharm, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$4,805 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $123,763 |
| RybelsusSemaglutide | 52 | $121,171 |
| OzempicSemaglutide | 74 | $107,022 |
| MounjaroTirzepatide | 74 | $92,505 |
| JardianceEmpagliflozin | 80 | $89,474 |
| FarxigaDapagliflozin Propanediol | 75 | $84,303 |
| TrulicityDulaglutide | 43 | $56,958 |
| VascepaIcosapent Ethyl | 51 | $39,760 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $37,832 |
| JanuviaSitagliptin Phosphate | 34 | $36,968 |
| LinzessLinaclotide | 24 | $29,214 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $24,956 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $24,458 |
| XareltoRivaroxaban | 19 | $16,673 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $14,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $555 | $228,193126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $517 | $149,463117 claims |
| PfizerEliquis | $407 | $123,76395 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $390 | $108,288120 claims |
| Boehringer IngelheimJardiance | $115 | $89,47480 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $146 | $62,29056 claims |
| MerckJanuvia, Janumet Xr | $78 | $51,52148 claims |
| AbbVieLinzess | $410 | $29,21424 claims |
| Johnson & JohnsonXarelto | $48 | $16,67319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Montgomery
- Leigh LunaMontgomery$69K
- Brandy YoungMontgomery$27K
- Angela RaybornMontgomery$22K
- Ashley MorrowMontgomery$21K
- Jackie ShumateMontgomery$19K
- Katrina Jones HarrisMontgomery$18K
- Brittney BarberMontgomery$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.